PeptidePedia The community reference

GLP-1 receptor (revision 3)

Old revision·08:50, 2 Jul 2024·BetaCellBoyd

This is an old revision of this page, as it stood at 08:50, 2 Jul 2024, saved by BetaCellBoyd with the summary clarify that the incretin effect is defined by the oral–intravenous comparison. It may differ substantially from the current revision, and any error it contains may since have been corrected.
GLP-1 receptor
SymbolGLP1R
FamilyClass B1 secretin-like GPCR
Endogenous ligandGlucagon-like peptide-1
Topic infobox · conventions

The GLP-1 receptor (GLP1R) is a class B G-protein-coupled receptor and the molecular target of Glucagon-like peptide-1 and of every drug in the GLP-1 receptor agonist class. It belongs to the secretin-like receptor family, whose members are characterised by a large extracellular domain that captures the C-terminal portion of a peptide ligand before the ligand N-terminus engages the transmembrane bundle.[1]

Activation couples principally to Gs, raising intracellular cAMP and activating protein kinase A and the exchange protein Epac2. In the pancreatic beta cell this cascade amplifies, but does not initiate, insulin exocytosis: the amplification requires a permissive rise in cytosolic calcium driven by glucose metabolism, which is the molecular basis of the glucose dependence that defines the class.[2]

Structure and ligand engagement

[edit]

GLP1R comprises an extracellular domain of about 130 residues, seven transmembrane helices and an intracellular C-terminal tail. Ligand binding follows the two-domain model characteristic of class B receptors: the C-terminal helix of the peptide is captured by the extracellular domain, which positions and concentrates the ligand, after which the peptide N-terminus inserts into a cavity formed by the transmembrane helices and drives the conformational change that couples to G protein.[1]

Cryo-electron microscopy structures of the agonist-bound, Gs-coupled receptor have resolved the sharp kink in transmembrane helix 6 that accompanies activation. The structures also explain why the first eight residues of the peptide are indispensable while the C-terminal half tolerates extensive modification: acylation, PEGylation and fusion partners are all attached distal to the pharmacophore.[3]

References

  1. ^ a b de Graaf C, Donnelly D, Wootten D, et al. "Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes." Pharmacological Reviews 68(4):954–1013 (2016). DOI:10.1124/pr.115.011395. PMID 27630114.
  2. ^ Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27(4):740–756 (2018). PMID 29617641.
  3. ^ Zhang Y, Sun B, Feng D, et al. "Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein." Nature 546(7657):248–253 (2017). DOI:10.1038/nature22394. PMID 28492058.